๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
2005 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Regeneron Pharmaceuticals
Phase 3
975
Liverpool, York, Bristol, London, Newcastle upon Tyne
2024-10-30
Recruiting
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
NCT06451770Hypercholesterolemia, Hypertriglyceridemia, Refractory Hyperlipidemia
Verve Therapeutics, Inc.
Phase 1
36
Liverpool, London, Manchester
2024-10-30
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
Pulmovant, Inc.
Phase 2
135
Cambridge, London, Clydebank
2024-10-29
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Sheffield, Cambridge, London
2024-10-24
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth
2024-10-24
Recruiting
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
NCT06343805Primary Myelofibrosis
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
London, Oxford
2024-10-23
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer
Phase 3
600
Blackburn, Westcliff-on-Sea, Edinburgh, Glasgow, London, Metropolitan Borough of Wirral, Swansea
2024-10-21
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
argenx
Phase 3
69
Birmingham, Bradford, Coventry, Glasgow, Leicester, London, Truro
2024-10-18
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Recruiting
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860Diabetic Peripheral Neuropathic Pain
Vertex Pharmaceuticals Incorporated
Phase 2
300
Birmingham, Dundee, Glasgow, Liverpool, London, Manchester, Nuneaton, Sheffield
2024-10-18
By invitation
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
NCT06559176Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Prime Medicine, Inc.
Phase 1/2
12
London
2024-10-17
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
Novartis Pharmaceuticals
Phase 2
251
Sheffield, Farnborough, London, Stoke-on-Trent
2024-10-17
Active, closed
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371Asthma
Amgen
Phase 1
21
Cambridge, London, Manchester
2024-10-16
Active, closed
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06598462Eosinophilic Esophagitis (EoE)
Uniquity One (UNI)
Phase 2
184
Whitechapel, London
2024-10-16
Recruiting
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
NCT06055959Generalized Myasthenia Gravis
UCB Biopharma SRL
Phase 2/3
8
Glasgow, London
2024-10-16
Recruiting
Study of ATX-01 in Participants With DM1
NCT06300307Myotonic Dystrophy 1
ARTHEx Biotech S.L.
Phase 1/2
56
London
2024-10-15
Active, closed
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Mirum Pharmaceuticals, Inc.
Phase 3
90
London
2024-10-14
Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168Primary Biliary Cholangitis
Ipsen
Observational
424
Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham
2024-10-14
Active, closed
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
NCT06504394Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
Merck Sharp & Dohme LLC
Phase 2
66
Bodelwyddan, London, Oxford, Manchester
2024-10-14
Recruiting
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449Huntington's Disease
Alnylam Pharmaceuticals
Phase 1
66
Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth
2024-10-14
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
Boehringer Ingelheim
Phase 2
588
Dundee, London, Manchester
2024-10-11
Active, closed
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060Episodic Migraine, Chronic Migraine
Ipsen
Phase 2
670
Exeter, Hull, Liverpool, London
2024-10-10
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
Incyte Corporation
Phase 3
346
Dudley, Ipswich, Liverpool, London, Poole, Redhill
2024-10-10
Active, closed
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
NCT06646289X-Linked Retinitis Pigmentosa
Janssen Research & Development, LLC
Phase 2
24
London
2024-10-10
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
200
Basingstoke, Bristol, London
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286HIV-1-infection
Gilead Sciences
Phase 3
609
Birmingham, Brighton, London
2024-10-09
Active, closed
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
NCT05417789TGCT
SynOx Therapeutics Limited
Phase 3
128
Leeds, London
2024-10-09
Active, closed
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299HIV-1-Infection
Gilead Sciences
Phase 3
600
Brighton, Great Maze Pond, London
2024-10-08
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
1,000
Exeter, Dundee, Larbert, Glasgow, London, Leicester, Manchester, Metropolitan Borough of Wirral
2024-10-07
Active, closed
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
NCT06513312Pre-Exposure Prophylaxis of HIV Infection
Gilead Sciences
Phase 2
268
Birmingham, Brighton, Liverpool, London, Manchester
2024-10-07
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Birmingham, Cambridge, Glasgow, Leicester, London, Manchester, Middlesbrough
2024-10-04
Active, closed
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
NCT06506955Advanced/Metastatic Cancer
Taiho Oncology, Inc.
Phase 2/3
15
London
2024-10-01
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
Belfast, Liverpool, London, Southampton
2024-09-30
Active, closed
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent ฮฒ-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
NCT06421636Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals
Phase 2
19
London
2024-09-30
Recruiting
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142Neoplasms
GlaxoSmithKline
Phase 1
845
Edinburgh, Glasgow, London, Manchester, Newcastle upon Tyne
2024-09-30
Recruiting
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT05663515Pancreatic Cancer
AstraZeneca
Observational
24,000
Edinburgh, London
2024-09-30
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
Sanofi
Phase 2
900
Cambridge, Glasgow, Bradford, Chertsey, London
2024-09-30
By invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency
Glycomine, Inc.
Phase 2
90
Birmingham, London
2024-09-30
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
GlaxoSmithKline
Phase 2
393
Bristol, Cambridge, Glasgow Strathclyde, Leeds West Yorkshire, Liverpool, London, Middlesbrough, Plymouth
2024-09-27
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
Stemline Therapeutics, Inc.
Phase 3
4,220
Truro, Brighton, London, Cheltenham, Northwood, Blackpool, Preston, Livingston
2024-09-27
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
GAP Innovations, PBC
Observational
1,200
Motherwell, London
2024-09-26
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
Longboard Pharmaceuticals
Phase 3
96
Newcastle upon Tyne, Glasgow, London
2024-09-25
Recruiting
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
Merus B.V.
Phase 3
700
Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton
2024-09-25
Recruiting
Trial of THEO-260 in Ovarian Cancer Patients
NCT06618235Ovarian Cancer
Theolytics Limited
Phase 1/2
44
Glasgow, London, Oxford
2024-09-24
Active, closed
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants โ‰ฅ18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794Acute Gastroenteritis, Norovirus Acute Gastroenteritis
ModernaTX, Inc.
Phase 3
37,864
High Wycombe, Runcorn, Truro, London, Orpington, Blackpool, Rochdale, Salford
2024-09-24
Active, closed
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
NCT06504446Refractory or Unexplained Chronic Cough
Nocion Therapeutics
Phase 2
455
Belfast, Bristol, Cottingham, London, Wythenshawe, Nottingham, North Shields
2024-09-24
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals
Phase 3
500
Glasgow, Leicester, Liverpool, London
2024-09-24
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
338
Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay
2024-09-23
Active, closed
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027Parkinson Disease
Cerevance
Phase 3
330
Newcastle upon Tyne, Bury, London, Plymouth
2024-09-20
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Bristol, Headington, London, Newcastle upon Tyne
2024-09-19
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Brighton, Glasgow, Leeds, London, Southampton
2024-09-18
Active, closed
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383Obesity
Novo Nordisk A/S
Phase 4
500
Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton
2024-09-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
400
Cambridge, Liverpool, London
2024-09-17
Active, closed
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504Hepatitis B
GlaxoSmithKline
Phase 2
153
Bristol Avon, London
2024-09-17
Active, closed
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
NCT06537999Multifocal Motor Neuropathy
Dianthus Therapeutics
Phase 2
46
London, Oxford, Salford
2024-09-17
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Dundee, Glasgow, Birmingham, Belfast, Cambridge, Edinburgh, Liverpool, London
2024-09-11
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
GlaxoSmithKline
Phase 3
440
Leicester, Birmingham, London
2024-09-11
Recruiting
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789Hemophilia B
Regeneron Pharmaceuticals
Phase 1/2
130
Glasgow, Birmingham, Cambridge, London
2024-09-11
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol
2024-09-11
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
AbbVie
Phase 2
540
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
179
Sheffield, London
2024-09-04
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
Takeda
Phase 3
2,099
High Wycombe, Ilford, Salford, London, Harrow
2024-09-04
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
London, Nottingham, Birmingham, Newcastle upon Tyne, Whitechapel
2024-09-04
Recruiting
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
NCT06547840Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
Epsilogen Ltd
Phase 1
45
Bristol, Edinburgh, Leeds, London, Southampton
2024-09-03
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
Gossamer Bio USA, Inc.
Phase 3
330
Cambridge, Clydebank, London, Newcastle, Sheffield
2024-09-03
Recruiting
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
NCT06576271Systemic Lupus Erythematosus
GlaxoSmithKline
Phase 1
142
Cambridge, Liverpool, London, Middlesex
2024-09-02
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Servier Bio-Innovation LLC
Phase 1/2
48
London, Sutton, Surrey
2024-08-31
Recruiting
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
NCT06610201Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Hemab ApS
Observational
200
London
2024-08-30
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Belfast, Birmingham, Bristol, Cambridge, Glasgow, Gloucester, Leicester, London
2024-08-30
Recruiting
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3
66
Cambridge, London
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
Gilead Sciences
Phase 3
640
Birmingham, Cambridge, Leeds, Leicester, London, Northwood
2024-08-28
Active, closed
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
NCT06540391Melanoma
Microbiotica Ltd
Phase 1
41
Brighton, Cambridge, Glasgow, London, Manchester, Newcastle, Sutton
2024-08-28
Recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06500884Multiple Myeloma
Janssen Research & Development, LLC
Phase 2
210
Belfast, Colchester, Eastbourne, Liverpool, London, Manchester, Newcastle upon Tyne
2024-08-26
Recruiting
Observational Study of Venus P-Valve
NCT05835349Right Ventricular Outflow Tract Dysfunction
Venus MedTech (HangZhou) Inc.
Observational
200
Leeds, London
2024-08-26
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
Zenas BioPharma (USA), LLC
Phase 2
93
Leicester, London, Swansea
2024-08-26
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
Cottingham, Edinburgh, Leeds, London
2024-08-26
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
Kite, A Gilead Company
Phase 3
452
Bristol, Cardiff, Leeds, London, Newcastle
2024-08-23
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
London, Manchester, Newcastle upon Tyne, Sutton
2024-08-22
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi
Phase 3
160
London, Inverness, Oxford
2024-08-21
Recruiting
Abbott Structural Heart Device Registry
NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices
Observational
2,500
London
2024-08-21
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
AbbVie
Phase 3
675
Plymouth, London, Southampton, Glasgow, Manchester, Newcastle upon Tyne
2024-08-19
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff
2024-08-16
Recruiting
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590Alzheimer Disease
Eli Lilly and Company
Phase 1
48
London, Sheffield, Southampton
2024-08-15
Active, closed
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620COPD
Uniquity One (UNI)
Phase 2
182
Wythenshawe, Bradford, High Wycombe, London
2024-08-14
Recruiting
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
NCT05861999Muscular Atrophy, Spinal
Hoffmann-La Roche
Phase 4
28
London
2024-08-14
Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
MOMA Therapeutics
Phase 1
220
London, Manchester, Newcastle upon Tyne
2024-08-13
Recruiting
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Novartis Pharmaceuticals
Phase 3
50
Cardiff, Glasgow, London
2024-08-13
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals
Phase 3
550
Bath, Glasgow, Leicester, London, Manchester, Oxford, Wolverhampton
2024-08-13
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Birmingham, Dundee, Glasgow, Greater London, Leeds, London
2024-08-12
Active, closed
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
NCT06313593Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
37
London, Oxford
2024-08-08
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
AbbVie
Phase 3
110
Cambridge, Sheffield, London, Norwich, Edinburgh
2024-08-08
Recruiting
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals
Phase 1/2
220
London, Manchester
2024-08-07
Active, closed
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06162572Non-small Cell Lung Cancer (NSCLC)
Servier Bio-Innovation LLC
Phase 1/2
102
London, Manchester
2024-08-07
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
London, Newcastle upon Tyne, Norwich, Nottingham, Plymouth, Southampton
2024-08-07
Active, closed
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045Diabetic Macular Edema (DME)
EyeBiotech Ltd.
Phase 2/3
984
London, York, Bradford, Bristol, Liverpool, Sunderland, Wolverhampton
2024-08-07
Active, closed
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109Alopecia Areata
Pfizer
Observational
450
Brighton, Dunfermline, Gloucester, London, Bath, Glasgow
2024-08-07
Recruiting
Study of XB010 in Subjects With Solid Tumors
NCT06545331Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
Exelixis
Phase 1
396
Leicester, London, Manchester
2024-08-06
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
BioNTech SE
Phase 2
110
Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne
2024-08-05
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
Merck Sharp & Dohme LLC
Phase 3
3,000
London
2024-08-05
Rows per page Showing 701–800 of 2005
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=8

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.